SCI Foundation, London, United Kingdom.
School of Public Health, Imperial College, London, United Kingdom.
PLoS Negl Trop Dis. 2021 Jan 19;15(1):e0009017. doi: 10.1371/journal.pntd.0009017. eCollection 2021 Jan.
Schistosomiasis affects nearly 220 million people worldwide, mainly in Sub-Saharan Africa (SSA). Preventive chemotherapy (PC) treatment, through regular mass-drug administration (MDA) of Praziquantel tablets remains the control measure of choice by Ministries of Health. Current guidelines recommend that 75% of school-aged children receive treatment. Many programmes, however, struggle to achieve this target. Given the risk of high reinfection rates, attaining sustained high levels of treatment coverage is essential. This study provides a comprehensive review of the barriers and facilitators operating at different levels of analysis, from the individual to the policy level, conditioning the uptake of PC for schistosomiasis in SSA.
METHODOLOGY/PRINCIPAL FINDINGS: A systematic literature search was conducted in several databases for publications released between January 2002 and 2019 that examined factors conditioning the uptake of Praziquantel in the context of MDA campaigns in SSA. A total of 2,258 unique abstracts were identified, of which 65 were selected for full text review and 30 met all eligibility criteria. Joanna Briggs Institute's Critical Appraisal and the Mixed-Methods Assessment tools were used to assess the strength of the evidence. This review was registered with PROSPERO (CRD42017058525). A meta-synthesis approach was used. Results indicated publication bias, with the literature focusing on East African rural settings and evidence at the individual and programmatic levels. The main influencing factors identified included material wellbeing, drug properties, knowledge and attitudes towards schistosomiasis and MDAs, fears of side effects, gender values, community and health systems support, alongside programme design features, like training, sensitisation, and provision of incentives for drug-distributors. The effect of these factors on determining Praziquantel uptake were explored in detail.
CONCLUSIONS/SIGNIFICANCE: Multiple determinants of treatment uptake were found in each level of analysis examined. Some of them interact with each other, thus affecting outcomes directly and indirectly. The promotion of context-based transdisciplinary research on the complex dynamics of treatment uptake is not only desirable, but essential, to design effective strategies to attain high levels of treatment coverage.
血吸虫病影响着全球近 2.2 亿人,主要集中在撒哈拉以南非洲(SSA)地区。预防性化疗(PC)治疗,即通过定期大规模药物管理(MDA)给予吡喹酮片剂,仍然是卫生部门首选的控制措施。目前的指南建议,有 75%的学龄儿童接受治疗。然而,许多方案都难以实现这一目标。鉴于高再感染率的风险,实现持续高水平的治疗覆盖率至关重要。本研究全面回顾了在个体到政策层面的不同分析水平上运作的障碍和促进因素,这些因素影响着 SSA 地区对血吸虫病 PC 的接受程度。
方法/主要发现:在多个数据库中进行了系统的文献检索,以查找 2002 年 1 月至 2019 年期间发表的研究论文,这些论文考察了在 SSA 的 MDA 运动中影响吡喹酮接种的因素。共确定了 2258 个独特的摘要,其中 65 个被选作全文审查,30 个符合所有资格标准。乔安娜·布里格斯研究所的批判性评价和混合方法评估工具用于评估证据的强度。本综述在 PROSPERO(CRD42017058525)上进行了注册。采用元综合方法。结果表明存在发表偏倚,文献主要集中在东非农村地区,以及个体和方案层面的证据。确定的主要影响因素包括物质福利、药物特性、对血吸虫病和 MDA 的知识和态度、对副作用的恐惧、性别价值观、社区和卫生系统支持,以及方案设计特征,如培训、宣传和为药物分发者提供激励。详细探讨了这些因素对确定吡喹酮接种的影响。
结论/意义:在每个检查的分析水平上都发现了治疗接受度的多个决定因素。其中一些因素相互作用,从而直接和间接地影响结果。促进基于背景的跨学科研究,了解治疗接受度的复杂动态,不仅是可取的,而且是必要的,以设计有效的策略来实现高水平的治疗覆盖率。